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Abstract
Aim: We evaluated the use of computerized quantification of wheezing and crackles compared to
a clinical score in assessing the effect of inhaled albuterol or inhaled epinephrine in infants with RSV
bronchiolitis.
Methods: Computerized lung sounds analysis with quantification of wheezing and crackles and a
clinical score were used during a double blind, randomized, controlled nebulized treatment pilot
study. Infants were randomized to receive a single dose of 1 mgr nebulized l-epinephrine or 2.5 mgr
nebulized albuterol. Computerized quantification of wheezing and crackles (PulmoTrack®) and a
clinical score were performed prior to, 10 minutes post and 30 minutes post treatment. Results
were analyzed with Student's t-test for independent samples, Mann-Whitney U test and Wilcoxon
test.
Results: 15 children received albuterol, 12 received epinephrine. The groups were identical at
baseline. Satisfactory lung sounds recording and analysis was achieved in all subjects. There was no
significant change in objective quantification of wheezes and crackles or in the total clinical scores
either within the groups or between the groups. There was also no difference in oxygen saturation
and respiratory distress.
Conclusion: Computerized lung sound analysis is feasible in young infants with RSV bronchiolitis
and provides a non-invasive, quantitative measure of wheezing and crackles in these infants. 
Trial registration number: ClinicalTrials.gov NCT00361452
Background
Bronchiolitis is the most common cause of hospitaliza-
tion for respiratory infection in infants under one year of
age. Respiratory syncytial virus (RSV) is the most common
etiology of acute bronchiolitis in infants. About 1–2% of
infants with bronchiolitis need to be hospitalized and
approximately 8% of these children require intensive care.
Of high risk patients, such as those with bronchopulmo-
nary dysplasia or congenital heart disease, about 30%
require intensive care [1-3].
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Treatment for most infants with bronchiolitis is usually
supportive, including oxygen, hydration and antipyretics.
The use of bronchodilator therapy remains controversial
[4,5], since the main tool used to measure response (clin-
ical score) is subjective and inaccurate. Thus different
studies showed different responses [6-11]. The one study
which used an objective measure (airway resistance)
showed improvement in only 30% of infants treated with
nebulized salbutamol [12]. Similar variable results were
reported when the effect of nebulized epinephrine in RSV
Bronchiolitis was studied using clinical scores [13-19].
Two studies which measured airway resistance [12,17]
were able to demonstrate a significant response to neb-
ulized Epinephrine, which was not apparent by clinical
criteria. Thus, objective physiological measurements may
be more sensitive and accurate in detecting response to
treatment than clinical assessments. The clinical score is a
crude instrument for measuring a clinical effect, as it is
observer-dependent and may therefore suffer from low
objectivity. Pulmonary function tests in infants are objec-
tive, but require sedation, which is problematic in acutely
ill infants [20]. Wheeze and crackle quantification by lung
sounds analysis methods is objective, non invasive and
has been shown to correlate with clinical status in asthma
and bronchiolitis [21-23]. The recording procedure is sim-
ple, requiring only the attachment of 4 ECG-size sensors
to the chest wall. A 30-second recording is often adequate,
but recording time can be extended as necessary [24], to
obtain good quality data, where wheezes and crackles are
detected and counted with high degree of accuracy. The
recording is, however, susceptible to outside noise inter-
ference, and requires a relatively quiet environment dur-
ing the recording. In addition, the outside-noise
elimination algorithm helps in eliminating outside noise
from the recording. The instrument is currently expensive,
but has the potential of both size and price reduction.
In this study we evaluated the feasibility of using compu-
terized quantification of wheezing and crackles and a clin-
ical score in measuring the effect of a single dose of
nebulized albuterol or nebulized epinephrine in infants
with RSV bronchiolitis. Our hypothesis was that auto-
mated quantification of wheezing and crackles is equal or
superior to the clinical score in assessing the infants'
response to treatment.
Methods
Patients
The study was approved by the Rambam Hospital Ethics
Committee. Subjects were recruited from infants treated at
the emergency department with proven RSV bronchiolitis
over a four-month period. Eligible infants complied with
the following: 1) Age 2 – 12 months; 2) First episode of
respiratory distress; 3) RSV antigen detected in oropharyn-
geal secretions by ELISA; 4) Informed consent signed by
parents. Infants younger than 2 months and those with
chronic lung disease, cardiac disease or other chronic con-
ditions were excluded.
Study design
Computerized lung sounds recording and analysis with
algorithms for wheeze and crackles counts (see below)
and a Clinical Score were performed during a double
blind, randomized, comparative study, comparing neb-
ulized salbutamol (2.5 mg diluted with 2.5 ml of 0.9%
saline) to nebulized l-epinephrine (1 mg diluted with 2
ml of 0.9% saline). Solutions were driven by compressed
oxygen of 5 l/min flow (giving a mean output of 0.4 ml/
min), and nebulized using a Hudson Up-Draft II neb-
ulizer (Hudson RCI, Temecula, CA, USA). Medication was
randomized prior to commencement of the study by the
hospital pharmacy independently of trial staff. Randomi-
zation was in blocks of 10 (5 salbutamol/5 epinephrine).
The two solutions, provided in identical containers, were
indistinguishable to the researchers.
Clinical Assessment
Clinical assessment was done prior to treatment, 10 min-
utes post and 30 minutes post treatment. At each point a
total clinical score was given (Table 1). The total clinical
score, modified from Wang et al. [25], was comprised of
the following parameters: wheezing, retractions, O2 satu-
ration, respiratory rate and heart rate. A score from 0 to 3
was given to each parameter (maximal total score – 15 –
indicated severely ill infants). All clinical assessments and
scores in all patients were performed by the same investi-
gator for consistency.
Computerized breath sounds recording and analysis
Recording and analysis of respiratory sounds were con-
ducted according to standardized methods previously
described [24]. Respiratory acoustic signals were recorded
from phonopneumography piezoelectric contact sensors
(PPG Sensors, Karmel Medical Acoustic Technologies
Ltd., Yokneam Illit, Israel) applied over right and left axil-
Table 1: Total clinical score of disease severity in young infants with bronchiolitis.
Score Wheeze Retractions Oxygen Saturation Respiratory Rate (per min.) Heart rate (per min.)
0N o n e N o n e ≥ 95% Normal (<35) < 140
1 Mild Mild 92 – 94% 35 – 44 140 – 159
2 Moderate Moderate 90 – 91% 45 – 54 160 – 179
3 Marked Severe < 90% > 55 ≥ 180BMC Pediatrics 2007, 7:22 http://www.biomedcentral.com/1471-2431/7/22
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lae (AR, AL) and both posterior bases (BR, BL) of the
lungs. The sensors are coin-shaped piezoelectric elements
with linear ±3dB frequency response from 75 to 2000 Hz,
a resonance at 2.7 kHz, a useable range that extends
beyond 4 kHz, and a built-in passive ambient noise rejec-
tion capability. The sensors were attached to the chest
with adhesive foam pads that further reduce ambient
noise interference and eliminate contact noise. All sensors
were connected to the PulmoTrack® (Model 1010, Karmel
Medical Acoustic Technologies Ltd. Yokneam Illit, Israel)
where signal conditioning (amplification X3000; band
pass filtration 80–4000 Hz at 24 dB/oct) was performed
prior to analog-to-digital conversion (12 bit, 11,025 sam-
ples per second per channel). Two other signals were
tracked: ambient noise – with an air-coupled microphone
placed near the patient, and chest impedance for measure-
ment of breathing activity (respiratory rate, phase and
amplitude). Wheeze detection was performed by a fast
Fourier transform (FFT)-based algorithm that was previ-
ously verified and found to have sensitivity of 91% and
specificity of 89% in wheeze detection when compared to
consensus assessment by a panel of pulmonary experts
who performed auscultation of the same respiratory
sounds [24]. Crackles were defined according to pub-
lished criteria [26,27], and a "crackle counter" algorithm
was developed analogous to one previously published by
Murphy et al. [26]. To verify accuracy of the automatic
crackle detector, all sound segments also underwent a
manual auditory analysis by two pulmonologists (LB,
SG), who were blinded to the results of the computerized
wheeze and crackle quantification.
The adhesive pad with which the sensors were applied to
the skin provided sound shielding. Environmental noise
such as speech, ringing, beeps, bumps etc, were identified
with an external microphone near the patient and elec-
tronically removed from the recording data. Occasional
motion artifact and the baby's own crying interfered with
the recording.
Lung sounds were recorded for a period of 5 minutes prior
to treatment, and then at 10 and at 30 minutes afterwards,
while the infant was relatively settled and not crying.
Recording times varied somewhat, and were extended
when necessary, to get enough "quiet breathing" data. To
obtain adequate averaging of the acoustic data, we ana-
lysed breath segments that contained at least 5 consecu-
tive interference-free breaths, for a total of 20 breaths.
Wheeze Rate (percent of time wheezing of total breath
time) [24] and crackle count (number of crackles per
breath) were determined by the PulmoTrack® for each
breath cycle, and averaged over the 20 breaths. It usually
took 4–6 hours per patient to edit and analyze the data.
Statistical Analysis
Statistics were performed by a biostatistician (TN). A
power calculation was not performed ahead of the study,
since this was a pilot study intended mainly to test the fea-
sibility and accuracy of automatic wheeze and crackle
quantification in a population of very young infants, not
intended to replace the clinical score, and with response
to treatment being secondary.
Demographic and clinical history variables, numerical
and categorical, were analyzed by Student t-test for inde-
pendent samples and Fisher exact test, respectively. Clini-
cal score and recorded acoustic breath sounds variables
were analyzed by non-parametric tests: Mann-Whitney U
test was used to compare between the groups, while Wil-
coxon signed rank test was used to compare within-group
differences over time. Relationship between clinical score
and crackle or wheeze counts, was tested by Spearman
correlation. P < 0.05 was considered as statistically signif-
icant.
Results
Over the study period 87 patients with bronchiolitis were
seen in the emergency department. Excluded were: 21
patients younger than 8 weeks, 22 seen on off hours when
investigators were unavailable, 12 with other significant
concurrent illnesses and 5 whose parents refused. Twenty-
seven infants whose parents signed an informed consent
(mean age 4.4 ± 0.8 months) were recruited, 12 received
epinephrine and 15 albuterol. The groups were well bal-
anced in terms of demographic and clinical parameters
(Table 2). Pre-study treatment with either inhaled bron-
chodilators or corticosteroids was not different in the two
groups.
Even though the crackle counter was not validated as part
of this study, there was complete agreement between cli-
nician and PulmoTrac results in all sound segments, in
off-line auditory analysis of the data. No significant differ-
ence in wheezing and crackles by computerized lung
Table 2: Demographic and clinical data of the sudy's 27 infants 
with RSV bronchiolitis.
Study Epinephrine Albuterol
Number 12 15
Age(months) 4.9 ± 0.8 4 ± 1.35
Gender(F/M) 4/8 4/11
Maternal smoking 5 7
Asthma in family 3 5
Atopy in family 3 2
Respiratory distress (days) 2.5 ± 0.48 2.2 ± 0.29
Poor feeding (days) 1.75 ± 0.44 2.2 ± 0.29
Fever (days) 1.41 ± 0.46 1.4 ± 0.32
Inh.Bronchodilators 3 2
Inh. Corticosteroids 1 1
Oral Corticosteroid 3 2
Poor feeding (not showing interest or eating significantly less (<75%) 
than normal) and Dyspnea (breathing fast, with effort and/or 
retractions) are according to parental history.BMC Pediatrics 2007, 7:22 http://www.biomedcentral.com/1471-2431/7/22
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sounds analysis was found between or within the groups
prior to, 10 minutes post and 30 minutes post treatment.
There was no significant change in objective quantifica-
tion of wheezes and crackles between the groups or in the
total clinical scores. Examples of acoustic wheeze detec-
tion in sonogram mode are shown in Figures 1, 2, 3. Fig-
ure 1 shows no response to albuterol, figure 2
demonstrates dramatic response to epinephrine with dis-
appearance of wheezing, while figure 3 shows transient
response with rebound wheezing at 30 minutes. Total
clinical score and acoustic results for both treatment
groups are summarized in Table 3.
Similar to the lung sounds, the total clinical score also did
not differ significantly within or between the groups prior
to, 10 minutes post and 30 minutes post treatment. In
individual parameter analysis, a significant difference in
favor of epinephrine was seen at 10 minutes in respiratory
rate (p < 0.04), and at 30 minutes in heart rate (p < 0.02).
There was no difference in oxygen saturation or respira-
tory distress score.
Discussion
This pilot study evaluated the use of computerized wheeze
and crackle quantification in assessing the acute response
to either nebulized albuterol or epinephrine in infants
with RSV-positive bronchiolitis. Although RSV Bronchi-
olitis is the most common cause of hospitalization for res-
piratory infection in infants, its therapy remains
controversial. Therefore, objective measures for assessing
response to treatment in RSV bronchiolitis are needed.
Modern computerized acoustic lung sounds analysis tech-
nology now allow on-line quantification of wheezing and
crackles, providing another objective tool for assessment
of disease activity in infants with bronchiolitis. In this
study, we demonstrated the feasibility of performing accu-
rate objective acoustic measurements in assessing acute
respiratory symptoms in young infants and the changes
that occur with treatment. Further studies are needed to
clarify its potential role as a clinical tool for assessing and
following infants with acute respiratory illnesses.
The possible effectiveness of nebulized epinephrine for
bronchiolitis, by reducing airway edema, was proposed
25 years ago [28] by Wohl and Chernick. Since then,
many studies have evaluated the effect of nebulized epine-
phrine vs. albuterol and/or placebo in infants with bron-
chiolitis. While some reported an improved effect of
epinephrine, others showed no, or even deleterious, effect
[14-20]. Overall, it is difficult to compare the various stud-
ies, due to their different dose schedules, populations and
outcome measures. The recent Cochrane Review on the
use of bronchodilators in bronchiolitis [29] concluded
that there is no strong evidence for their benefit, either
Sonogram of subject treated with albuterol, showing no  response Figure 1
Sonogram of subject treated with albuterol, showing no 
response.
Table 3: Results of the response to nebulized epinephrine and 
albuterol in respiratory, heart rate and total clinical scores, 
computerized wheeze count and computerized crackle count.
Time Epinephrine Albuterol p
Respiratory Rate Score*
0 2.17 ± 0.27 2.4 ± 0.19 0.54
10 1.83 ± 0.3 § 2.67 ± 0.16 0.04
30 2.17 ± 0.34 2.47 ± 0.22 0.55
Heart Rate Score*
0 0.67 ± 0.22 1.0 ± 0.24 0.35
10 0.92 ± 0.23 1.2 ± 0.2 0.35
30 0.75 ± 0.13 § 1.4 ± 0.16 0.02
Total Clinical Score*
0 5.67 ± 0.71 7.27 ± 0.6 0.07
10 5.67 ± 0.83 7.13 ± 0.6 0.18
30 5.75 ± 0.77 7.47 ± 0.68 0.12
Computerized Wheeze Rate*
0 9.1 ± 3.4 5.5 ± 3.08 0.53
10 5.47 ± 3.26 9.11 ± 2.52 0.15
30 7.1 ± 3.63 11.9 ± 4.5 0.20
Computerized Crackle Count*
0 1.88 ± 0.59 1.74 ± 0.42 0.68
10 2.48 ± 0.92 1.14 ± 0.23 0.37
30 2.26 ± 0.7 1.31 ± 0.33 0.35
* Mean ± SD
§Significant resultBMC Pediatrics 2007, 7:22 http://www.biomedcentral.com/1471-2431/7/22
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short or long term. Similar to these previous RSV studies,
our study indicates that there is no significant overall dif-
ference in the short-term effect of nebulized epinephrine
compared to albuterol in these infants, when assessed by
both objective acoustic analysis of wheezing and crackles
and a combined clinical score. However, minor differ-
ences in heart and respiratory rates in favour of epine-
phrine were found, the clinical significance of which is
uncertain.
Crackles and wheezing are the cardinal auscultatory find-
ings in bronchiolitis. In asthma, the degree of wheezing
measured as Tw/Ttot has been shown to correlate with
severity of airway obstruction [30]. Tal et al. [23] studied
16 infants with bronchiolitis and wheezing, of whom 7
responded to albuterol. However, his study population
consisted of older infants (mean age 9.4 vs. 4.4 months),
the majority of whom had either previous episodes of
wheezing, family history of asthma or atopy or bronchop-
ulmonary dysplasia. They were therefore at higher risk of
wheezing with viral infections or other triggers. In bron-
chiolitis, due to distal airway edema and secretions, crack-
les are often produced. Young babies with RSV
bronchiolitis characteristically have more crackles,
explaining the difference in wheezing between the two
patient populations. Reduction of edema and drying of
secretions by epinephrine might be expected to result in
reduced crackles. Modern computerized acoustic lung
sounds analysis technology (mainly due to fast high-RAM
computers) now allow rapid accurate quantification of
wheezing and crackles, providing an objective tool for
assessment of disease activity in infants with bronchioli-
tis. In our study to evaluate this tool, we found no overall
short-term advantage of nebulized epinephrine compared
to albuterol as assessed by computerized wheeze and
crackle quantification and by total clinical score. How-
ever, it should be noted that the sample size in this pilot
study was designed primarily to evaluate the acoustic
method and therefore does have adequate power to detect
clinical response. A larger study is necessary to assess the
Sonogram of subject treated with epinephrine showing tran- sient response with relapse Figure 3
Sonogram of subject treated with epinephrine showing tran-
sient response with relapse.
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Sonogram of subject treated with epinephrine showing signif- icant reduction in wheezing Figure 2
Sonogram of subject treated with epinephrine showing signif-
icant reduction in wheezing.
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correlation between the computerized crackle and wheeze
counts and the Clinical Score in response to treatment in
RSV bronchiolitis.
Conclusion
Computerized lung sound analysis is feasible in young
infants with RSV bronchiolitis and provides a non-inva-
sive, quantitative measure of wheezing and crackles. In a
pilot study using computerized lung sound analysis, we
could not demonstrate any significant overall short-term
effect of either nebulized epinephrine or albuterol, nor a
difference between them.
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